239 related articles for article (PubMed ID: 24615630)
1. α-adrenergic blockers for the treatment of lower-urinary-tract symptoms and dysfunction in women.
Boyd K; Hilas O
Ann Pharmacother; 2014 Jun; 48(6):711-22. PubMed ID: 24615630
[TBL] [Abstract][Full Text] [Related]
2. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.
Djavan B; Marberger M
Eur Urol; 1999; 36(1):1-13. PubMed ID: 10364649
[TBL] [Abstract][Full Text] [Related]
3. Treatment of lower urinary tract symptoms in benign prostatic hypertrophy with α-blockers.
Belayneh M; Korownyk C
Can Fam Physician; 2016 Sep; 62(9):e523. PubMed ID: 27629686
[No Abstract] [Full Text] [Related]
4. Terazosin for benign prostatic hyperplasia.
Wilt TJ; Howe RW; Rutks IR; MacDonald R
Cochrane Database Syst Rev; 2002; (4):CD003851. PubMed ID: 12519611
[TBL] [Abstract][Full Text] [Related]
5. Tamsulosin for benign prostatic hyperplasia.
Wilt TJ; Mac Donald R; Rutks I
Cochrane Database Syst Rev; 2003; (1):CD002081. PubMed ID: 12535426
[TBL] [Abstract][Full Text] [Related]
6. Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms.
Lowe FC
Clin Ther; 2004 Nov; 26(11):1701-13. PubMed ID: 15639685
[TBL] [Abstract][Full Text] [Related]
7. Role of phosphodiesterase type 5 inhibitors for lower urinary tract symptoms.
Miller MS
Ann Pharmacother; 2013 Feb; 47(2):278-83. PubMed ID: 23386068
[TBL] [Abstract][Full Text] [Related]
8. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.
Gacci M; Corona G; Salvi M; Vignozzi L; McVary KT; Kaplan SA; Roehrborn CG; Serni S; Mirone V; Carini M; Maggi M
Eur Urol; 2012 May; 61(5):994-1003. PubMed ID: 22405510
[TBL] [Abstract][Full Text] [Related]
9. Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group.
Na YJ; Guo YL; Gu FL
J Med; 1998; 29(5-6):289-304. PubMed ID: 10503165
[TBL] [Abstract][Full Text] [Related]
10. [Drug therapy of benign prostatic hyperplasia syndrome with alpha 1-receptor blockers. Basic principles and clinical results].
Oelke M; Höfner K; Berges RR; Jonas U
Urologe A; 2002 Sep; 41(5):425-41. PubMed ID: 12426859
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of PDE5 inhibitors alone or in combination with alpha-blockers for the treatment of erectile dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and meta-analysis.
Yan H; Zong H; Cui Y; Li N; Zhang Y
J Sex Med; 2014 Jun; 11(6):1539-45. PubMed ID: 24621088
[TBL] [Abstract][Full Text] [Related]
12. α1-Blockers in Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction: Is Silodosin Different?
Roehrborn CG; Cruz F; Fusco F
Adv Ther; 2017 Jan; 33(12):2110-2121. PubMed ID: 27752927
[TBL] [Abstract][Full Text] [Related]
13. Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia.
Garimella PS; Fink HA; Macdonald R; Wilt TJ
Cochrane Database Syst Rev; 2009 Oct; (4):CD007360. PubMed ID: 19821408
[TBL] [Abstract][Full Text] [Related]
14. alpha-Blockade improves symptoms suggestive of bladder outlet obstruction but fails to relieve it.
Rossi C; Kortmann BB; Sonke GS; Floratos DL; Kiemeney LA; Wijkstra H; de la ROSETTE JJ
J Urol; 2001 Jan; 165(1):38-41. PubMed ID: 11125359
[TBL] [Abstract][Full Text] [Related]
15. Alpha-blockers for treating neurogenic lower urinary tract dysfunction in patients with multiple sclerosis: A systematic review and meta-analysis. A report from the Neuro-Urology Promotion Committee of the International Continence Society (ICS).
Schneider MP; Tornic J; Sýkora R; Abo Youssef N; Mordasini L; Krhut J; Chartier-Kastler E; Davies M; Gajewski J; Schurch B; Bachmann LM; Kessler TM
Neurourol Urodyn; 2019 Aug; 38(6):1482-1491. PubMed ID: 31099113
[TBL] [Abstract][Full Text] [Related]
16. Sexual Dysfunction Related to Drugs: a Critical Review. Part V: α-Blocker and 5-ARI Drugs.
La Torre A; Giupponi G; Duffy D; Conca A; Cai T; Scardigli A
Pharmacopsychiatry; 2016 Jan; 49(1):3-13. PubMed ID: 26569417
[TBL] [Abstract][Full Text] [Related]
17. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension.
Drake MJ; Chapple C; Sokol R; Oelke M; Traudtner K; Klaver M; Drogendijk T; Van Kerrebroeck P;
Eur Urol; 2015 Feb; 67(2):262-70. PubMed ID: 25070148
[TBL] [Abstract][Full Text] [Related]
18. Medical therapy for benign prostatic hyperplasia: a review of the literature.
Clifford GM; Farmer RD
Eur Urol; 2000 Jul; 38(1):2-19. PubMed ID: 10859436
[TBL] [Abstract][Full Text] [Related]
19. The role of combination medical therapy in benign prostatic hyperplasia.
Greco KA; McVary KT
Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
[TBL] [Abstract][Full Text] [Related]
20. Silodosin: a selective alpha1A-adrenergic receptor antagonist for the treatment of benign prostatic hyperplasia.
Schilit S; Benzeroual KE
Clin Ther; 2009 Nov; 31(11):2489-502. PubMed ID: 20109995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
